其他摘要：Background : Malignant mesothelioma is an aggressive cancer with no effective treatment options. Of phytochemicals, tocotrienol (T3), a member of vitamin E, is one of the most potent anti-mesothelioma agents, but the effectiveness in vivo is quite limited, due to its low bioavailability. In this study, we investigated if the oral treatment of -T3 inclusion with -cyclodextrin (CD) could improve the bioavailability and anticancer activity of the T3. Findings : Using nude mice bearing MSTO-211H cells (a human malignant mesothelioma cell line), the effect of -T3 inclusion with -CD on -T3 level in tumor tissues, tumor growth, and its related mRNA levels were examined. The difference of tumor growth between the two groups had no statistical significance, but the latter showed a lower tendency compared with the former. In linked with this observation, the level of vascular endothelial growth factor mRNA required for in vivo tumor growth in -T3 inclusion with -CD group was lower than that in -T3 group, on the contrary, the level of -T3 level showed an opposite tendency. Conclusion : Our study demonstrated that the bioavailability of -T3 was improved by an oral administration of a novel -T3 inclusion complex with CD. Furthermore, the improvement of the bioavailability contributed to the increase of anticancer activity of -T3 in vivo . Key words : Anti-cancer agent, bioavailability, cyclodextrin, mesothelioma, tocotrienol.
